Abbott has launched a pivotal clinical trial to see if its deep-brain stimulation approach can make headway against treatment ...

Apelin receptor agonist azelaprag is designed to combine well with GLP-1 drugs, boosting weight loss while preserving muscle ...

A new type of mpox, clade Ib, has been spreading rapidly within the Democratic Republic of Congo and leaking outside the ...

Embecta has secured an FDA clearance for its first wearable insulin delivery system, with a patch pump designed for people ...

Arsenal Biosciences is moving on up. The cell therapy company has added on $325 million in ammunition with big-name backers ...

Eli Lilly’s hunt for obesity targets has led it to the dark genome. | Eli Lilly’s hunt for obesity targets has led it to the ...

Aelis Farma’s hopes of securing a quick, positive decision on a $100 million option payment have gone up in smoke. | Aelis ...

Athira Pharma’s tumultuous journey to phase 2/3 Alzheimer’s disease data has ended in failure. | Athira Pharma’s tumultuous ...

Parexel, a global contract research organization headquartered in Durham, North Carolina, is beefing up its ability to gather real-world data by bringing Mike D’Ambrosio on board as senior vice ...

Call it a case of good chemistry: Acepodia, a biotech based on Nobel Prize-winning science, is entering into a new ...

The efficacy data are less compelling. Recursion said MRI scans showed “a trend towards reduced lesion volume and hemosiderin ...

The phase 1/2 Prevnar 20 head-to-head data that Vaxcyte revealed for its VAX-31 in adults ages 50 and older are “exceptional” ...